Search clinical trials for: insulin glargine treatment

Total 13736 results

University of Pennsylvania

Withdrawn

Pilot Study of Clinician-supported Patient Self-management of Hospital Insulin Therapy

Diabetes Mellitus

United States
Sanofi

Completed

Effect of Soliqua 100/33 on Time in Range From Continuous Glucose Monitoring in Insulin-naive Patients With Very Uncontrolled Type 2 Diabetes Mellitus (Soli-CGM)

Type 2 Diabetes Mellitus

United States
Sanofi

Completed

Evaluation of the Efficacy and Safety of Insulin Glargine 300 U/mL in Patients With Type 2 Diabetes Mellitus Uncontrolled on Other Kinds of Insulin (ARTEMIS-DM)

Type 2 Diabetes Mellitus

Argentina, Colombia, Egypt, Hong Kong, India, Indonesia, Lebanon, Malaysia, Peru, Philippines, Saudi Arabia, South Africa, Thailand, Turkey
Gan and Lee Pharmaceuticals, USA

Completed

Gan & Lee Insulin Glargine Target Type (2) Evaluating Research (GLITTER 2)

Diabetes Mellitus, Type 2

United States
Sandra Sobel

Completed

Remission Through Early Monitored Insulin Therapy - Duration Month (REMIT-DM)

Type 2 Diabetes Mellitus

United States
Sanofi

Completed

DOMME Dose Optimization Multicentric Mexican Evaluation (DOMME)

Diabetes Mellitus, Type 2

Mexico
Boston Medical Center
Novo Nordisk A/S

Completed

Novolog vs. Fiasp Insulin in Non-critically Ill Hospitalized Patients With Type 2 Diabetes Mellitus (In-FI)

Type 2 Diabetes Treated With Insulin

United States
Vanderbilt University Medical Center

Completed

Use of Insulin Glargine to Treat Diabetic Ketoacidosis

Diabetic Ketoacidosis

United States
Eli Lilly and Company

Completed

A Study in Patients With Type 2 Diabetes Mellitus (IMAGINE 2)

Diabetes Mellitus, Type 2

United States, Brazil, Germany, Israel, Italy, United Kingdom, Australia, Hungary, Puerto Rico, Romania, Russian Federation, Spain, Poland, Canada, Greece, Turkey, Mexico, New Zealand, South Africa, Argentina, Finland, Lithuania, Sl...
Population Health Research Institute
Sanofi

Completed

Remission Evaluation of a Metabolic Intervention for Type 2 Diabetes With IGlarLixi (REMIT-iGL)

Type 2 Diabetes Mellitus

Canada
Sanofi

Completed

Lantus Versus NPH: Comparison in Insulin Naive People Not Adequately Controlled With at Least One Oral Anti Diabetics (OAD) Treatment (LANCELOT)

Diabetes Mellitus, Type 2

Brazil, Thailand, Slovakia, Poland, Netherlands, Kuwait, Mexico, Korea, Republic of, Czech Republic, Egypt, France, Italy, Romania, Russian Federation, Sweden, Switzerland, United Arab Emirates
Profil Institut für Stoffwechselforschung GmbH
Sanofi

Completed

Adjunctive Therapy of Exenatide or Sitagliptin to Insulin Glargine in Type 2 Diabetes

Type 2 Diabetes

Germany
Sanofi

Completed

Evaluation of Insulin Glargine/Lixisenatide Fixed Ratio Combination in Patients With Type 2 Diabetes Insufficiently Controlled With Oral Antidiabetic Drug(s) (Lixilan-O-AP)

Type 2 Diabetes Mellitus

China, Korea, Republic of, Malaysia, Taiwan
Providence Health & Services

Withdrawn

Comparison Study of Insulin Glargine and NPH Insulin

Diabetes

United States
Ain Shams University

Not yet recruiting

Insulin Degludec vs Insulin Glargine for Glycemic Control in Critical Illness Hyperglycemia

Critical Illness | Insulin | Glycemic Control
Novo Nordisk A/S

Completed

A Research Study to Compare Two Types of Insulin: Insulin 287 and Insulin Glargine in People With Type 2 Diabetes Who Have Not Used Insulin Before

Diabetes Mellitus, Type 2

Poland, United States, Croatia, Spain, Slovakia, Germany, Hungary
The University of Texas Health Science Center,...

Completed

Effectiveness of Subcutaneous Glargine On The Time To Closure of The Anion Gap in Patients Presenting to the Emergency Department With Diabetic Keto-acidosis (GT-COG)

Diabetic Ketoacidosis

United States
Hospital Universitario San Ignacio

Recruiting

Risk of Hypoglycemia in the Transition From Inpatient to Outpatient Setting. Comparative Study of Basal-bolus Insulin Versus Basal Insulin Plus GLP-1 Analogue

Diabetes Mellitus, Type 2 Treated With Insulin

Colombia
Sanofi

Completed

Comparison of Glucose Values and Variability Between TOUJEO and TRESIBA During Continuous Glucose Monitoring in Type 1 Diabetes Patients (inRange)

Type 1 Diabetes Mellitus

Turkey, Netherlands, Brazil, United States, Germany, Hungary, United Kingdom
Eli Lilly and Company

Completed

Hyperglycemia and Cardiovascular Outcomes With Type 2 Diabetes (IONM)

Diabetes Mellitus, Type 2 | Acute Myocardial Infarction

Canada, Croatia, Czech Republic, Germany, Hungary, India, Israel, Lebanon, Poland, Romania, Russian Federation, Slovakia, Slovenia, South Africa, Spain, Turkey, United Kingdom
University of Palermo

Completed

Effects of Degludec/Liraglutide on Time in Range, Inflammation and Endothelial Function vs Insulin Basal Bolus in Diabetic Inpatients

Diabetes Mellitus, Type 2

Italy
LMC Diabetes & Endocrinology Ltd.

Completed

The Effect of Soliqua on Glucose Variability in Type 2 Patients Among South Asians (VARIATION 2 SA)

Diabetes Mellitus, Type 2

Canada
GlaxoSmithKline
PPD

Completed

Safety and Efficacy of Albiglutide + Insulin Glargine Versus Insulin Lispro + Insulin Glargine Subjects With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

Spain, Germany, Hungary, Italy, Philippines, France, United States, Mexico, Brazil, South Africa, Korea, Republic of, Canada, Poland, United Kingdom
Servier (Tianjin) Pharmaceutical Co. LTD.

Completed

Study of Combination Therapy of Gliclazide MR and Basal Insulin Versus Insulin Monotherapy to Treat Type 2 Diabetes (CODMS)

Type 2 Diabetes

China
Merck Sharp & Dohme LLC

Completed

A Study of the Safety and Efficacy of MK-1293 Compared to Lantus™ in Participants With Type 1 Diabetes Mellitus (T1DM) (MK-1293-003)

Type 1 Diabetes Mellitus
Joslin Diabetes Center
Eli Lilly and Company; Amylin Pharmaceuticals, LLC.

Completed

The Effect of Exenatide Compared to Lantus Insulin on Vascular Function in Type 2 Diabetes

Type 2 Diabetes Mellitus

United States
Sanofi

Terminated

Insulin Glargine Injection Treatment in Place of Thiazolidinedione (TZD), Sulfonylurea, or Metformin in Triple Agent Therapy for Type 2 Diabetes Mellitus (T2DM) Adult Subjects With Unsatisfactory Control

Diabetes Mellitus, Type 2

United States
Sanofi

Completed

Insulin Glulisine, Insulin Lispro and Insulin Glargine in Type 1 or 2 Diabetes Mellitus

Diabetes Mellitus

China
Mount Sinai Hospital, Canada
Canadian Institutes of Health Research (CIHR); University of Toronto

Completed

Preserving Beta-cell Function in Type 2 Diabetes With Exenatide and Insulin (PREVAIL) (PREVAIL)

Type 2 Diabetes

Canada
Sanofi

Completed

Comparison of Two Treatment Regimens in Patients With Type 2 Diabetes After Short-term Intensive Insulin Therapy (SWITCH)

Type 2 Diabetes Mellitus

China
Eli Lilly and Company

Completed

A Study of Insulin Peglispro and Glargine on Fats in Participants With Type 1 Diabetes

Diabetes Mellitus, Type 1

Denmark
Sanofi

Completed

Insulin Glulisine in Diabetes Mellitus, Type 2 (GINGER)

Diabetes Mellitus, Type 2

France, Spain, Italy, Belgium, Germany, Poland, Portugal, Czech Republic, Slovakia, Australia, Netherlands, Sweden, United Kingdom, Switzerland, Romania
Eli Lilly and Company

Completed

A Study to Compare the Effect of a Double Dose of Two Long-acting Insulin Therapies in Participants With Type 2 Diabetes (IMAGINE 8)

Type 2 Diabetes Mellitus

Germany, United States
Fundación Pública Andaluza Progreso y Salud

Completed

Insulin in Total Parenteral Nutrition (INSUPAR)

Diabetes Mellitus

Spain
Centre hospitalier de l'Université de Montréal...
Radiological Society of North America; Centre de Recherche du Centre Hospitalier... and other collaborators

Completed

Study of Liraglutide Versus Insulin on Liver Fat Fraction in Patients With Type 2 Diabetes (LIRAINS)

Type 2 Diabetes | Nonalcoholic Fatty Liver Disease | Nonalcoholic Steatohepatitis

Canada
Eli Lilly and Company

Completed

A Study To Compare the Effects of Insulin Peglispro and Glargine on Insulin Sensitivity and Meal Time Insulin Requirements in Type 2 Diabetics

Diabetes Mellitus, Type 2

United States
Sanofi

Terminated

Better Acceptance of Single Injection Apidra Added to Once Daily Lantus Versus Twice Daily Premixed Insulin in Real Life Use Setting (BASAAL PLUS)

Diabetes Mellitus, Type 2

Netherlands
Northwestern University

Completed

Study of Glycemic Control on Liver Transplantation Outcomes

Hyperglycemia | Rejection | Evidence of Liver Transplantation

United States
Xiangya Hospital of Central South University

Recruiting

Efficacy and Safety Of Different Regimens In Patients With Type 2 Diabetes Receiving Intensive Insulin Therapy

Type 2 Diabetes Mellitus

China
Elaine Chow
Sanofi

Completed

Toujeo Versus NPH Self-titration Study

Diabetes Mellitus, Type 2

Hong Kong
University of Miami

Terminated

Simplified Insulin Regimen for the Elderly

Type 2 Diabetes Mellitus

United States
M.D. Anderson Cancer Center
Novo Nordisk A/S

Terminated

Effect of Tight Control of Blood Glucose During Hyper-CVAD Chemotherapy For Acute Lymphocytic Leukemia (ALL)

Lymphoma | Leukemia

United States
Eli Lilly and Company

Completed

Effects of Insulin in Perceived Mood Symptoms in Patients With Type 2 Diabetes

Type 2 Diabetes

United States
Eli Lilly and Company

Completed

24 Hour Plasma Glucose Profiles Comparing Lispro Mix 75/25 vs. Glargine

Type 2 Diabetes

United States
Imperial College London

Completed

Resolution of Type 2 Diabetes Mellitus: Intensive vs. Conventional Glycaemic Control After Obesity Surgery (GLUCOSURG1)

Obesity | Type 2 Diabetes Mellitus

United Kingdom
Novo Nordisk A/S

Completed

A Trial Comparing Efficacy and Safety of Insulin Degludec and Insulin Glargine in Insulin naïve Subjects With Type 2 Diabetes (BEGIN™)

Diabetes Mellitus, Type 2 | Diabetes

United States, Canada, South Africa, Romania, Brazil, China, Ukraine
National Taiwan University Hospital
Chang Gung Memorial Hospital; Taipei Medical University Shuang Ho Hospital

Unknown

Insulin Glargine Versus Regular Insulin Based Regimens in Glycemic Control After Acute Stroke (ICAS)

Hyperglycemia | Acute Stroke

Taiwan
Eli Lilly and Company

Withdrawn

A Study of Insulin Peglispro (LY2605541) in Participants With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

United States
Novo Nordisk A/S

Completed

A Trial Investigating the Safety, Tolerability, and Distribution and Activity in the Body of NNC0148-0000-0287 Injected Under the Skin in Healthy Subjects and in Subjects With Type 1 Diabetes

Healthy | Diabetes | Diabetes Mellitus, Type 1

Germany
Sanofi

Completed

Insulin Glargine (Lantus) vs Sulfonylurea (SU) for BETA Cell Function (BETA Study)

Type 2 Diabetes Mellitus

Korea, Republic of

Search clinical trials for: insulin glargine treatment

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Colombia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations